---
layout: minimal-medicine
title: Daclatasvir
---

# Daclatasvir
### Generic Name
Daclatasvir

### Usage
Daclatasvir is an antiviral medication specifically used to treat chronic Hepatitis C virus (HCV) infection.  It's crucial to understand that Daclatasvir is *not* used alone; it's always administered in combination with other antiviral drugs, most commonly sofosbuvir, and sometimes ribavirin, depending on the patient's genotype (strain of HCV), the presence of cirrhosis (liver scarring), and prior treatment history.  The combination therapy targets different stages of the HCV life cycle, leading to a more effective cure.  Daclatasvir primarily works against genotypes 1 and 3 of HCV. While it may be used off-label for other genotypes (2, 4, 5, and 6), the efficacy and safety data might not be as comprehensive.

### Dosage
Daclatasvir is typically administered orally as a 60 mg tablet once daily.  The precise dosage regimen depends heavily on several factors:

* **HCV Genotype:** Treatment duration varies based on the HCV genotype (1, 2, 3, 4, 5, or 6) and whether the patient has been treated before.
* **Cirrhosis:** The presence and severity of cirrhosis (liver scarring) significantly influence treatment duration and the need for additional medications like ribavirin. Patients with decompensated cirrhosis (severe liver damage) generally require longer treatment durations and may need ribavirin.
* **Prior Treatment:** Patients who have previously failed HCV treatment may require different regimens compared to treatment-naive patients.
* **Organ Transplantation:** Patients who have received liver or kidney transplants often require specific treatment strategies involving Daclatasvir in combination with sofosbuvir and ribavirin.

**Because the dosage regimens are complex and individualized, it's absolutely essential to consult a healthcare provider or refer to the official prescribing information for precise dosage instructions.** The information provided here is for general understanding only and should not be used for self-medication.


### Side Effects
Common side effects (occurring in more than 10% of patients) may include:

* Fatigue
* Headache
* Nausea
* Anemia

Less common side effects (1-10% of patients) can include:

* Drowsiness
* Insomnia
* Skin rash
* Diarrhea
* Increased serum lipase levels (an enzyme in the pancreas)

Serious but less frequent side effects (less than 1%, often reported post-marketing or in case studies) include:

* Reactivation of Hepatitis B virus (HBV) in patients co-infected with HBV

**If you experience any adverse effects, particularly those that are severe or persistent, contact your healthcare provider immediately.**

### How it Works
Daclatasvir is a non-structural protein 5A (NS5A) inhibitor.  NS5A is a protein crucial for the Hepatitis C virus's replication and assembly. By inhibiting NS5A, Daclatasvir interferes with the virus's ability to multiply and produce new virus particles. This, in combination with other antivirals targeting other parts of the virus's life cycle, leads to a significant reduction in the viral load and ultimately, a sustained virologic response (SVR), meaning a cure.

### Precautions
* **Contraindications:** Daclatasvir is contraindicated in individuals with hypersensitivity to the drug or its components. It should not be used with strong CYP3A inducers (medications that increase the metabolism of Daclatasvir).  Combined use with certain other medications, such as specific CYP3A inhibitors, requires careful monitoring and dose adjustments by a healthcare professional.
* **Drug Interactions:** Daclatasvir can interact with other medications, especially those metabolized by the CYP3A4 enzyme.  Always inform your healthcare provider about all medications, herbal supplements, and over-the-counter drugs you are taking.
* **Hepatitis B Reactivation:**  There's a risk of Hepatitis B reactivation in patients co-infected with Hepatitis B and C.  Testing for Hepatitis B before starting Daclatasvir is crucial, and careful monitoring during and after treatment is essential.
* **Cardiovascular Risks:** Some patients experience bradycardia (slow heart rate), especially those already with cardiovascular disease.  Careful monitoring is necessary.
* **Pregnancy and Breastfeeding:**  The safety and efficacy of Daclatasvir in pregnant or breastfeeding women have not been established.  Consult with your doctor to discuss risks and benefits.


### FAQs

* **Q: Can I take Daclatasvir with food?** A: Daclatasvir can be taken with or without food.

* **Q: How is Daclatasvir stored?** A: Store Daclatasvir as directed by your pharmacist, typically at room temperature and away from moisture and light.

* **Q: How long does it take to see results?** A:  Viral load reductions are typically monitored during treatment and after completion.  Sustained virologic response (cure) is assessed several months after treatment completion.

* **Q: What if I miss a dose?** A:  Take the missed dose as soon as you remember, unless it's almost time for the next dose. Do not double the dose.

* **Q:  Is Daclatasvir a cure for Hepatitis C?** A:  When used in combination therapy as prescribed, Daclatasvir can lead to a sustained virologic response (SVR), which is considered a cure. However, this is dependent on adhering to the prescribed treatment regimen and regular monitoring.

**Disclaimer:** This information is for educational purposes only and should not be considered medical advice. Always consult with a healthcare professional for diagnosis, treatment, and management of Hepatitis C.  The provided dosage information is a simplification and should not be used in place of consulting the official prescribing information.  Specific treatment plans should be determined by a physician based on the individual's medical history and condition.
